Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -- | -- | 51.60% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | -- | -- | 25.64% | ||
| Operating Income | -- | -- | -25.64% | ||
| Income Before Tax | -- | -- | -34.49% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -- | -- | -34.49% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -- | -- | -34.49% | ||
| EBIT | -- | -- | -25.64% | ||
| EBITDA | -- | -- | -29.19% | ||
| EPS Basic | -- | -- | -27.95% | ||
| Normalized Basic EPS | -- | -- | -21.61% | ||
| EPS Diluted | -- | -- | -19.32% | ||
| Normalized Diluted EPS | -- | -- | -18.11% | ||
| Average Basic Shares Outstanding | -- | -- | 2.31% | ||
| Average Diluted Shares Outstanding | -- | -- | -1.82% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||